The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease

Sohag University

Status: Enrolling

Conditions: Sickle Cell Disease

Treatments: Diagnostic Test: urinary endothelin 1

Study type: Observational

Funder types: Other

Identifiers

NCT06158945

soh_Med_23_10_01MS

Details and patient eligibility

About

Sickle cell disease (SCD) refers to a group of hemoglobinopathies that include mutations in the gene encoding the beta subunit of hemoglobin. Within the umbrella of SCD, many subgroups exist, namely sickle cell anemia (SCA), hemoglobin SC disease (HbSC), and hemoglobin sickle-beta-thalassemia (beta-thalassemia positive or beta-thalassemia negative). Several other minor variants within the group of SCDs also, albeit not as common as the varieties mentioned above. It is essential to mention the sickle cell trait (HbAS), which carries a heterozygous mutation and seldom presents clinical signs or symptoms. Sickle cell anemia is the most common form of SCD

Enrollment: 30 estimated patients

Sex: All

Ages: 1 to 18 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• The patients fulfilling all the following criteria will be included:
• Patients with sickle cell disease in the age range of 1-18years.

Exclusion criteria

• Patients diagnosed to have coexistent renal disease before the study